We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy Study in Acute Ischaemic Stroke (VASST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00144014
Recruitment Status : Completed
First Posted : September 2, 2005
Last Update Posted : June 3, 2016
Sponsor:
Information provided by (Responsible Party):
Vernalis (R&D) Ltd

Brief Summary:
A Phase II study to evaluate the safety and efficacy of five dose levels of study drug in acute ischaemic stroke

Condition or disease Intervention/treatment Phase
Stroke Drug: V10153 Phase 2

Detailed Description:
An open label, dose escalation study where patients with acute ischaemic stroke will receive a single intravenous dose of study drug. There will be five dose levels with groups of 10 patients in each. Escalation to higher doses will occur following review of safety data from the previous dose.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 49 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Multi-centre, Two-part Study to Evaluate the Safety and Efficacy of Study Drug in Acute Ischaemic Stroke.
Study Start Date : August 2005
Primary Completion Date : November 2008
Study Completion Date : March 2009

Arm Intervention/treatment
Experimental: V10153, 1.0 mg/kg
Single acute intravenous bolus dose
Drug: V10153
Single acute intravenous bolus dose up to 10 mg/kg
Other Names:
  • Code Names: V10153, BB-10153
  • CAS Registry Number: 931101-84-7
  • Proposed INN: Troplasminogen alfa
Experimental: V10153, 2.5 mg/kg
Single acute intravenous bolus dose
Drug: V10153
Single acute intravenous bolus dose up to 10 mg/kg
Other Names:
  • Code Names: V10153, BB-10153
  • CAS Registry Number: 931101-84-7
  • Proposed INN: Troplasminogen alfa
Experimental: V10153, 5.0 mg/kg
Single acute intravenous bolus dose
Drug: V10153
Single acute intravenous bolus dose up to 10 mg/kg
Other Names:
  • Code Names: V10153, BB-10153
  • CAS Registry Number: 931101-84-7
  • Proposed INN: Troplasminogen alfa
Experimental: V10153, 7.5 mg/kg
Single acute intravenous bolus dose
Drug: V10153
Single acute intravenous bolus dose up to 10 mg/kg
Other Names:
  • Code Names: V10153, BB-10153
  • CAS Registry Number: 931101-84-7
  • Proposed INN: Troplasminogen alfa
Experimental: V10153, 10 mg/kg
Single acute intravenous bolus dose
Drug: V10153
Single acute intravenous bolus dose up to 10 mg/kg
Other Names:
  • Code Names: V10153, BB-10153
  • CAS Registry Number: 931101-84-7
  • Proposed INN: Troplasminogen alfa



Primary Outcome Measures :
  1. To establish the safety of five dose levels (1.0, 2.5, 5, 7.5 and 10 mg/kg)of V10153 in patients with acute ischaemic stroke. [ Time Frame: Ongoing ]

Secondary Outcome Measures :
  1. To compare recanalisation rates across dose levels. [ Time Frame: Ongoing ]
  2. To compare clinical outcome between treatments by NIHSS, Modified Rankin Scale and Barthel Index. [ Time Frame: Post-study completion ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Summary of Inclusion Criteria:

  1. Onset of new neurological signs of stroke within 3 to 9 hours of the time to initiation of treatment
  2. Aged 18 and above
  3. Provide consent
  4. Cerebral CT scan to show findings of early ischaemic changes consistent with the clinical diagnosis and an ASPECT score of between 5 and 10 inclusive.
  5. NIHSS score greater than 5 or less than or equal to 20.

Summary of Exclusion Criteria:

  1. Coma
  2. Stroke with unknown time of onset
  3. Minor stroke symptoms and sings (<6 points on the NIHSS) which are rapidly improving by the time of randomisation.
  4. Major stroke symptoms and signs (>20 on the NIHSS)
  5. History of stroke in previous 6 weeks
  6. History of brain tumours
  7. CT scan results in an ASPECT score of <5
  8. Haemorrhagic risk
  9. Abnormal laboratory values
  10. Positive urine pregnancy test, lactation or parturition within previous 30 days.
  11. Weight >135 kg
  12. Uncontrolled hypertension.
  13. Raised blood glucose
  14. History of or current serious illness
  15. Participation in another clinical trial within 4 weeks of drug administration


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00144014


  Show 28 Study Locations
Sponsors and Collaborators
Vernalis (R&D) Ltd
Investigators
Principal Investigator: Michael Hill Foothills Hosptial

Responsible Party: Vernalis (R&D) Ltd
ClinicalTrials.gov Identifier: NCT00144014     History of Changes
Other Study ID Numbers: V10153-2S-01
First Posted: September 2, 2005    Key Record Dates
Last Update Posted: June 3, 2016
Last Verified: May 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Vernalis (R&D) Ltd:
Acute
Ischaemic
Stroke

Additional relevant MeSH terms:
Stroke
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases